DANBURY, Conn. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA Inc., a wholly-owned subsidiary of IQVIA Holdings Inc. (“IQVIA”) (NYSE: IQV), today announced that it has placed approximately $1.65 billion of USD and EUR term B loans:

• USD term B loans of $950 million due 2025, priced at LIBOR plus a margin of 175 basis points, which represents a 25 basis point margin improvement compared to IQVIA Inc.’s existing USD term B loans.
• EUR term B loans of approximately $700 million due 2025, priced at EURIBOR plus a margin of 200 basis points, consistent with IQVIA Inc.’s existing EUR term B loans. The EUR term B loans have a floor of 50 basis points, which represents a 25 basis point improvement compared to IQVIA Inc.’s existing EUR term B loans.

The proceeds of the additional term B loans were used to pay down IQVIA Inc.’s revolving credit facility, refinance $650 million of existing USD term B loans due 2024 and to pay fees and expenses in connection with the transactions.

About IQVIA

IQVIA (NYSE:IQV) is a leading global provider of advanced analytics, technology solutions, and contract research services to the life sciences industry. Formed through the merger of IMS Health and Quintiles, IQVIA applies human data science — leveraging the analytic rigor and clarity of data science to the ever-expanding scope of human science — to enable companies to reimagine and develop new approaches to clinical development and commercialization, speed innovation, and accelerate improvements in healthcare outcomes. Powered by the IQVIA CORE™, IQVIA delivers unique and actionable insights at the intersection of large-scale analytics, transformative technology and extensive domain expertise, as well as execution capabilities. With more than 55,000 employees, IQVIA conducts operations in more than 100 countries.